{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:18:28Z","timestamp":1793085508142,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171978"],"award-info":[{"award-number":["82171978"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971647"],"award-info":[{"award-number":["81971647"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13360-w","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T20:09:11Z","timestamp":1735330151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic value of interim PET\/CT in GCB and non-GCB DLBCL: comparison of the Deauville five-point scale and the \u0394SUVmax method"],"prefix":"10.1186","volume":"24","author":[{"given":"Na","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0700-3626","authenticated-orcid":false,"given":"Yan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8867-7985","authenticated-orcid":false,"given":"Jinhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"issue":"1","key":"13360_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"13360_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s11864-021-00906-4","volume":"22","author":"JM Logue","year":"2021","unstructured":"Logue JM, Chavez JC. How to sequence therapies in diffuse large B-Cell lymphoma Post-CAR-T cell failure. Curr Treat Options Oncol. 2021;22(12):112.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"13360_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382.","journal-title":"Blood"},{"issue":"4","key":"13360_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3747\/co.26.5421","volume":"26","author":"P Skrabek","year":"2019","unstructured":"Skrabek P, Assouline S, Christofides A, MacDonald D, Prica A, Sangha R, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Curr Oncol. 2019;26(4):253\u201365.","journal-title":"Curr Oncol"},{"issue":"1","key":"13360_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41408-020-00403-1","volume":"11","author":"S Harrysson","year":"2021","unstructured":"Harrysson S, Eloranta S, Ekberg S, Enblad G, Jerkeman M, Wahlin BE, et al. Incidence of relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021;11(1):9.","journal-title":"Blood Cancer J"},{"key":"13360_CR6","doi-asserted-by":"publisher","first-page":"102443","DOI":"10.1016\/j.ctrv.2022.102443","volume":"110","author":"S Poletto","year":"2022","unstructured":"Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev. 2022;110:102443.","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"13360_CR7","first-page":"289","volume":"120","author":"M Ernst","year":"2023","unstructured":"Ernst M, D\u00fchrsen U, Hellwig D, Lenz G, Skoetz N, Borchmann P. Diffuse large B-Cell lymphoma and related entities. Dtsch Arztebl Int. 2023;120(17):289\u201396.","journal-title":"Dtsch Arztebl Int"},{"issue":"20","key":"13360_CR8","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1002\/cncr.33772","volume":"127","author":"ME Juweid","year":"2021","unstructured":"Juweid ME, Mueller M, Alhouri A, A-Risheq MZ, Mottaghy FM. Positron emission tomography\/computed tomography in the management of Hodgkin and B-cell non-hodgkin lymphoma: an update. Cancer. 2021;127(20):3727\u201341.","journal-title":"Cancer"},{"issue":"16","key":"13360_CR9","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.3390\/cancers13163952","volume":"13","author":"A Gallamini","year":"2021","unstructured":"Gallamini A, Kurlapski M, Zaucha JM. FDG-PET\/CT for the management of Post-chemotherapy residual Mass in Hodgkin lymphoma. Cancers (Basel). 2021;13(16):3952.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"13360_CR10","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1007\/s00330-020-06815-8","volume":"30","author":"N Aide","year":"2020","unstructured":"Aide N, Fruchart C, Nganoa C, Gac AC, Lasnon C. Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy. Eur Radiol. 2020;30(8):4623\u201332.","journal-title":"Eur Radiol"},{"issue":"1","key":"13360_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2967\/jnumed.122.264106","volume":"64","author":"F Ricard","year":"2023","unstructured":"Ricard F, Cheson B, Barrington S, Trotman J, Schmid A, Brueggenwerth G, et al. Application of the Lugano Classification for Initial Evaluation, staging, and Response Assessment of Hodgkin and Non-hodgkin Lymphoma: the PRoLoG Consensus Initiative (Part 1-Clinical). J Nucl Med. 2023;64(1):102\u20138.","journal-title":"J Nucl Med"},{"issue":"3","key":"13360_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1053\/j.semnuclmed.2022.11.001","volume":"53","author":"L Zanoni","year":"2023","unstructured":"Zanoni L, Bezzi D, Nanni C, Paccagnella A, Farina A, Broccoli A, et al. PET\/CT in Non-hodgkin Lymphoma: an update. Semin Nucl Med. 2023;53(3):320\u201351.","journal-title":"Semin Nucl Med"},{"issue":"1","key":"13360_CR13","first-page":"CD012643","volume":"1","author":"A Aldin","year":"2020","unstructured":"Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2020;1(1):CD012643.","journal-title":"Cochrane Database Syst Rev"},{"key":"13360_CR14","first-page":"648572","volume":"2015","author":"N Sun","year":"2015","unstructured":"Sun N, Zhao J, Qiao W, Wang T. Predictive value of interim PET\/CT in DLBCL treated with R-CHOP: meta-analysis. Biomed Res Int. 2015;2015:648572.","journal-title":"Biomed Res Int"},{"issue":"8","key":"13360_CR15","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2967\/jnumed.120.255034","volume":"62","author":"L Kurch","year":"2021","unstructured":"Kurch L, H\u00fcttmann A, Georgi TW, Rekowski J, Sabri O, Schmitz C, et al. Interim PET in diffuse large B-Cell lymphoma. J Nucl Med. 2021;62(8):1068\u201374.","journal-title":"J Nucl Med"},{"issue":"4","key":"13360_CR16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.122.264740","volume":"64","author":"L Michaud","year":"2023","unstructured":"Michaud L, Bantilan K, Mauguen A, Moskowitz CH, Zelenetz AD, Sch\u00f6der H. Prognostic value of 18F-FDG PET\/CT in diffuse large B-Cell lymphoma treated with a risk-adapted Immunochemotherapy Regimen. J Nucl Med. 2023;64(4):536\u201341.","journal-title":"J Nucl Med"},{"issue":"13","key":"13360_CR17","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1007\/s00259-022-05918-2","volume":"49","author":"Z Kiamanesh","year":"2022","unstructured":"Kiamanesh Z, Ayati N, Sadeghi R, Hawkes E, Lee ST, Scott AM. The value of FDG PET\/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging. 2022;49(13):4661\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"13360_CR18","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.2967\/jnumed.123.265871","volume":"64","author":"E Itti","year":"2023","unstructured":"Itti E, Blanc-Durand P, Berriolo-Riedinger A, Kanoun S, Kraeber-Bod\u00e9r\u00e9 F, Meignan M, et al. Validation of the \u2206SUVmax for interim PET interpretation in diffuse large B-Cell lymphoma on the basis of the GAINED clinical trial. J Nucl Med. 2023;64(11):1706\u201311.","journal-title":"J Nucl Med"},{"issue":"5","key":"13360_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41408-022-00649-x","volume":"12","author":"SH Desai","year":"2022","unstructured":"Desai SH, Pederson L, LaPlant B, Mwangi R, Maurer M, Young JR, et al. PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. Blood Cancer J. 2022;12(5):78.","journal-title":"Blood Cancer J"},{"issue":"25","key":"13360_CR20","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood.2019003277","volume":"135","author":"H Sch\u00f6der","year":"2020","unstructured":"Sch\u00f6der H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, et al. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 clinical trial. Blood. 2020;135(25):2224\u201334.","journal-title":"Blood"},{"issue":"1","key":"13360_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2967\/jnumed.120.244145","volume":"62","author":"J Rekowski","year":"2021","unstructured":"Rekowski J, H\u00fcttmann A, Schmitz C, M\u00fcller SP, Kurch L, Kotzerke J, et al. Interim PET evaluation in diffuse large B-Cell lymphoma using published recommendations: comparison of the Deauville 5-Point scale and the \u2206SUVmax Method. J Nucl Med. 2021;62(1):37\u201342.","journal-title":"J Nucl Med"},{"issue":"5","key":"13360_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.25460","volume":"94","author":"Y Liu","year":"2019","unstructured":"Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604\u201316.","journal-title":"Am J Hematol"},{"issue":"7","key":"13360_CR23","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1182\/bloodadvances.2022008543","volume":"7","author":"P Torka","year":"2023","unstructured":"Torka P, Groman A, Wong J, Nichols J, Kader A, Mavis C, et al. Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL. Blood Adv. 2023;7(7):1146\u201355.","journal-title":"Blood Adv"},{"issue":"3","key":"13360_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12185-019-02690-2","volume":"110","author":"R Nyilas","year":"2019","unstructured":"Nyilas R, Farkas B, Bicsko RR, Magyari F, Pinczes LI, Illes A, et al. Interim PET\/CT in diffuse large B-cell lymphoma may facilitate identification of good-prognosis patients among IPI-stratified patients. Int J Hematol. 2019;110(3):331\u20139.","journal-title":"Int J Hematol"},{"key":"13360_CR25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/MNM.0000000000000553","volume":"37","author":"R de Oliveira Costa","year":"2016","unstructured":"de Oliveira Costa R, Neto HA, Siqueira S, de Lage LAPC, de Paula HM, Coutinhoet AM, et al. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the Rituximab era. Nucl Med Commun. 2016;37:1095\u2013101.","journal-title":"Nucl Med Commun"},{"issue":"1","key":"13360_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12149-016-1123-6","volume":"31","author":"J Kim","year":"2017","unstructured":"Kim J, Lee JO, Paik JH, Lee WW, Kim SE, Song YS. Different predictive values of interim 18F-FDG PET\/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma. Ann Nucl Med. 2017;31(1):1\u201311.","journal-title":"Ann Nucl Med"},{"issue":"27","key":"13360_CR27","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"key":"13360_CR28","doi-asserted-by":"publisher","first-page":"1153784","DOI":"10.3389\/fradi.2023.1153784","volume":"3","author":"J Wu","year":"2023","unstructured":"Wu J, Xia Y, Wang X, Wei Y, Liu A, Innanje A, et al. uRP: an integrated research platform for one-stop analysis of medical images. Front Radiol. 2023;3:1153784.","journal-title":"Front Radiol"},{"issue":"1","key":"13360_CR29","first-page":"5","volume":"9","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-hodgkin\u2019s lymphoma. Med Sci (Basel). 2021;9(1):5.","journal-title":"Med Sci (Basel)"},{"issue":"23","key":"13360_CR30","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","volume":"33","author":"C Mamot","year":"2015","unstructured":"Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, et al. Final results of a prospective evaluation of the Predictive Value of Interim Positron Emission Tomography in patients with diffuse large B-Cell lymphoma treated with R-CHOP-14 (SAKK 38\/07). J Clin Oncol. 2015;33(23):2523\u201329.","journal-title":"J Clin Oncol"},{"issue":"25","key":"13360_CR31","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1182\/blood.2020005649","volume":"135","author":"M Meignan","year":"2020","unstructured":"Meignan M, Gallamini A. \u2206SUVmax for interim PET in DLBCL: old is new. Blood. 2020;135(25):2202\u20133.","journal-title":"Blood"},{"issue":"9","key":"13360_CR32","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1002\/cam4.3867","volume":"10","author":"S Tokola","year":"2021","unstructured":"Tokola S, Kuitunen H, Turpeenniemi-Hujanen T, Kuittinen O. Interim and end-of-treatment PET-CT suffers from high false-positive rates in DLBCL: Biopsy is needed prior to treatment decisions. Cancer Med. 2021;10(9):3035\u201344.","journal-title":"Cancer Med"},{"issue":"1","key":"13360_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13550-024-01074-w","volume":"14","author":"W Zhao","year":"2024","unstructured":"Zhao W, Wu X, Huang S, Wang H, Fu H. Evaluation of therapeutic effect and prognostic value of 18F-FDG PET\/CT in different treatment nodes of DLBCL patients. EJNMMI Res. 2024;14(1):20.","journal-title":"EJNMMI Res"},{"issue":"9","key":"13360_CR34","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","volume":"5","author":"JJ Eertink","year":"2021","unstructured":"Eertink JJ, Burggraaff CN, Heymans MW, D\u00fchrsen U, H\u00fcttmann A, Schmitz C, et al. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Adv. 2021;5(9):2375\u201384.","journal-title":"Blood Adv"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13360-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13360-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13360-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T21:24:48Z","timestamp":1735334688000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13360-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13360"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13360-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data collection and the methods used in this study were carried out in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The data collection program for this study was approved by Shanghai General Hospital Research Ethics Committee (No.2024064) with a waiver for individual informed consent for this retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1583"}}